본문으로 건너뛰기
cccskills
무료GitHub에 공개

endo-csii-structured-assessment-pre-prescribe

Performs a structured pre‑prescription evaluation of mental/psychological status, prior diabetes self‑care adherence, willingness/interest in CSII, and availability for follow‑up visits. Triggers include: 'Evaluating pump candidacy', 'Pre‑pump checklist: psych, adherence, motivation, follow-up'.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

설치 방법 보기

포함된 파일(1)

  • SKILL.md2.8 KB

SKILL.md(원문)

설치하기 전에 에이전트에게 전달되는 지시 내용을 확인할 수 있습니다.

Perform structured assessment before prescribing CSII

STEP 1 — Gather Information

Collect: mental/psychological health (e.g., depression, anxiety, cognitive impairment), documented adherence to diabetes self‑care (SMBG/CGM frequency, carbohydrate counting, appointment attendance), patient‑expressed willingness and interest in trying an insulin pump, and confirmed ability to attend required follow‑up visits (typically quarterly). Document each domain in a structured checklist.

STEP 2 — Rule In / Rule Out

If any domain is markedly deficient (active untreated psychiatric illness, chronic non‑adherence, explicit unwillingness, or inability to commit to follow‑up), rule out CSII candidacy and address the deficiency; otherwise, rule in the patient for further stratification.

STEP 3 — Classify or Stratify

Classify readiness as: Ready (all four domains adequate), Conditionally Ready (one or two mild concerns that can be remedied with targeted support), or Not Ready (multiple or severe concerns requiring alternative therapy).

STEP 4 — Decide

If Ready, proceed to prescribe CSII and initiate device education/training; if Conditionally Ready, implement a remediation plan (e.g., adherence coaching, mental health referral, follow‑up scheduling) and reassess in 4–6 weeks; if Not Ready, continue optimized MDI or consider other adjunctive therapies and revisit pump candidacy after optimization.

Clinical Guardrails / Mimics / Pitfalls

Do not prescribe CSII based solely on A1C or patient request without assessing psychosocial and adherence factors. Avoid overlooking untreated depression or anxiety, which can impair pump use and safety. Never assume willingness; verify interest through explicit discussion. Ensure follow‑up feasibility before prescribing to prevent abandonment and DKA risk.

Concrete Clinical Example

A 34‑year‑old with T1DM, A1C 8.6%, reports checking glucose 4×/day, counts carbohydrates, attends endocrinology visits quarterly, denies depression/anxiety, expresses strong interest in a pump, and can commit to monthly check‑ins initially. All domains are adequate → classified as Ready → CSII prescribed with structured education plan initiated.

Source: Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2534

리뷰

아직 리뷰가 없습니다. 사용해 본 소감을 남겨 주세요.

댓글

로그인 없이 쓸 수 있습니다. 사용 후기, 질문, 작동하지 않은 환경 등을 편하게 남겨 주세요.

아직 댓글이 없습니다. 첫 댓글을 남겨 보세요.

보내면 바로 공개됩니다. 이메일 주소나 전화번호 같은 개인 정보는 쓰지 마세요. URL은 2개까지입니다.

0 / 1,000자

이 양식은 reCAPTCHA로 보호되며 Google 개인정보처리방침 및 서비스 약관이 적용됩니다.

같은 저장소의 스킬

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

dromlakhani의 스킬 모두 보기

이 스킬의 문제 신고